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Assembly of RAS molecules into complexes at the cell membrane is critical for RAS signaling. 
We previously showed that oncogenic KRAS codon 61 mutations increase its affinity for RAF, 
raising the possibility that KRAS
Q61H
, the most common KRAS mutation at codon 61, 
upregulates RAS signaling through mechanisms at the level of RAS assemblies. We show here 
that KRAS
Q61H
 exhibits preferential binding to RAF relative to PI3K in cells, leading to 
enhanced MAPK signaling in in vitro models and human NSCLC tumors. X-ray crystallography 
of KRAS
Q61H
:GTP revealed that a hyper-dynamic switch 2 allows for a more stable interaction 
with switch 1, suggesting that enhanced RAF activity arises from a combination of absent 
intrinsic GTP hydrolysis activity and increased affinity for RAF. Disruption of KRAS
Q61H
 
assemblies by the RAS oligomer-disrupting D154Q mutation impaired RAF dimerization and 





 oligomers were disrupted by RAF mutations that disrupt RAF-RAF 
interactions. KRAS
Q61H
 cells show enhanced sensitivity to RAF and MEK inhibitors individually 
whereas combined treatment elicited synergistic growth inhibition. Furthermore, KRAS
Q61H
 
tumors in mice exhibited high vulnerability to MEK inhibitor, consistent with cooperativity 
between KRAS
Q61H
 and RAF oligomerization and dependence on MAPK signaling. These 
findings support the notion that KRAS
Q61H
 and functionally similar mutations may serve as 
predictive biomarkers for targeted therapies against the MAPK pathway. 
SIGNIFICANCE: Findings show that oncogenic KRAS
Q61H
 forms a cooperative RAS-RAF 
ternary complex which renders RAS-driven tumors vulnerable to MEKi and RAFi, thus 
establishing a framework for evaluating RAS biomarker-driven targeted therapies. 
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Activating KRAS mutations are major genetic drivers of aggressive cancers such as 
pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and lung adenocarcinoma 
(LUAD) (1). Development of RAS-directed therapeutic strategies has been challenging, but 
recent progress with KRAS
G12C
 inhibitors (2-4) has ignited new hope for addressing RAS-driven 
diseases. However, the G12C story also suggests that other RAS mutations may require 
mutation-specific approaches derived from detailed understanding of mechanisms (5). Most 
oncogenic RAS mutations occur at codons 12, 13, and 61 (1). These mutations lead to 
accumulation of RAS-GTP, the activated form of RAS. However, the transforming potency of 
these mutations differ, and they occur at different rates across cancer types, suggesting that 
selection occurs in disease because of functional dissimilarities between mutations (1,5). 
Although we have no mechanistic explanations for why certain RAS mutations occur selectively 





 activation occurs because of rapid nucleotide exchange (RNE) 
stemming from structural changes in the protein, instead of insensitivity to GTPase-activating 
proteins (GAPs) (6,7). This suggests that RNE mutants will occur selectively in contexts where 
RNE is supported, and/or where GAPs are deficient. On the other hand, the forces driving 
selection of other mutations, such as codon 13 and codon 61 mutations, are poorly understood.  
Formation of RAS complexes at the cell membrane is essential for RAS signaling activity in 
many contexts (8-12). These complexes appear to be highly dynamic suggesting that specific 
RAS mutations may differentially alter the behavior of these sensitive complexes. Recently we 
reported a RAS mutation, D154Q, which neutralizes the suppressive effects of KRAS
WT
 in the 
context of oncogenic KRAS. This mutation was designed based on a RAS-RAS interaction that 
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occurs via an α4-α5 interface seen in some RAS crystal structures (12). Recent NMR studies of 
RAS molecules bound to nanodisks also showed a similar structural model that utilizes the α4-α5 
interface, although there were some differences (13). Nevertheless, the dynamic nature of these 
complexes suggests that multiple forms likely exist and other competing models have also been 
proposed, although they have not yet been evaluated in cell-based systems (14,15). Regardless, 
the ability to manipulate at least one form of RAS-RAS interaction using the D154Q mutation 
enables studies of how specific oncogenic RAS mutations may affect RAS assemblies.  
RAS mutations that alter the strength of interactions with specific effectors have potential to 
alter the behavior of RAS complexes. One such mutation is KRAS
Q61H
, which shows a 
combination of exceptionally low GTPase activity and a relatively high affinity for RAF (16). 
Here we directly compared KRAS
Q61H
, a rare mutation in human disease overall (<1% of 
KRAS), but the most common codon 61 mutation for KRAS in human diseases, to KRAS
G12D
, 
the most common cancer-associated RAS mutation overall. We used laboratory models and 
clinical samples derived from a large patient cohort to evaluate the importance KRAS 
multimerization on MAPK and PI3K activity. We also evaluated the structural basis of the 
preference of KRAS
Q61H
 for MAPK signaling using x-ray crystallography. Our data suggest a 
unique interdependence between RAS and RAF multimerization for KRAS
Q61H
, but not 
KRAS
G12D
. This interdependence leads to increased signaling through the MAPK pathway, and 
sensitivity to RAF and MEK inhibitors, suggesting that certain codon 61 mutations in RAS may 
be useful as predictive biomarkers for RAS-directed therapies. 
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Materials and Methods 
Plasmids  
pcDNA3-CFP (Cat#13030), pcDNA3-YFP (Cat#13033), PIK3CA (Cat#16643), and 
pBABEpuro-c-RAF (Cat#51124) plasmids were purchased from Addgene. KRAS
WT
 plasmid 
was sourced from DNA2.0 (Cat#95005). KRAS
WT
, PIK3CA, and c-RAF full-length fragments 

























 mutants were generated via site directed 







 and the counterparts with D154Q 
mutation were generated using Gibson Assembly approach. For bacterial expression purpose, 
Raf-1-RBD
1-149 
plasmid (Cat#13338) was bought from Addgene, and p110γ-RBD
206-311 
was 
constructed via Gibson Assembly using p110γ-RBD
206-311
 fragment synthesized from IDT and 
Raf-1-RBD
1-149 
plasmid as a vector. The sequences were confirmed by DNA sequencing.  
 
Cell Lines 




 cells were generous 
gifts from Dr. Mariano Barbacid’s lab and the generation has been previously described (17). All 




 retroviral plasmids 
were created by point mutagenesis from pBABE HA-tagged KRAS
WT
 plasmid (provided by 
Channing Der, Addgene plasmid # 75282). Retroviruses were generated by co-transfection of 
pBABE plasmids together with pAmpho plasmid into HEK293T cells using FuGENE® HD 
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 MEFs followed by 2 wks of puromycin selection (1 μg/mL) in DMEM medium 
supplemented with 10% fetal bovine serum (FBS), 100 g/ml penicillin and 100 units/ml 




clones, cells were then cultured in the presence of 4-
hydroxytamoxifen (4OHT) (Sigma, H7904) for another 2 wks in order to achieve complete 
deletion of endogenous KRas alleles. Doxycycline (DOX) (Sigma, D9891) inducible Flp-In T-
REx 293 cells expressing KRAS G12D, G13D, and Q61H and the counterparts with D154Q 
mutation were generated by following manufacturer’s instructions (Thermal Fisher). In brief, 






 and the 
counterparts with D154Q mutation were co-transfected with pOG44 into Flp-In T-REx 293 cells 
followed by 2 wks of hygromycin (100 µg/mL) and blasticidin (15 µg/mL) selection in DMEM 
medium supplemented with 10% Tet-free FBS (Omega Scientific, FB-15). DOX (2 ng) was 
added to induce protein expression and initiate RAS dimerization (8). All cell lines used in the 
study tested negative for Mycoplasma as determined by the Mycoplasma Plus PCR Primer Set 
(Agilent) and the most recent test was done in December 2019. The length of time between 
thawing and the use in the described experiments was always < 3 months.   
 
Cellular Thermal Shift Assay 
The protein thermal stability was evaluated via cellular thermal shift assay (CETSA) as 
previously described (18). HEK293T cells were co-transfected with KRAS mutants and c-RAF 
or p110α for 48 hrs. with the supplement of 10% FBS, then the protein samples were subject to 
thermal treatment using PCR machine. The resultant supernatants were then tested via Western 
blotting assay.   
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HEK293T cells were grown in 10% FBS and RAS-GTP levels were assessed by Active 
Ras Pull-down Detection Kit (Thermal Fisher) using Raf-1-RBD and p110γ-RBD fused to GST 
to bind active (GTP-bound) RAS. Protein lysates (500 g) were incubated with 100 μl 
glutathione resin and GST protein binding domains for 1 hr at 4ºC to capture active small 
GTPases according to the manufacturer’s protocol. After washing, the bound GTPase was 
recovered by eluting the GST-fusion protein from the glutathione resin. The purified GTPase 
was detected by Western blotting assay using anti-RAS antibody. 
 
Western Blot Analysis 
Cells from in vitro culture, ex vivo explants, or NSCLC patient tumor specimens were 
lysed in RIPA lysis buffer (Thermo Fisher) supplemented with protease and phosphatase 
inhibitor cocktails (Sigma). The proteins of interest were probed with corresponding antibodies. 
Primary antibodies included anti-RAS (CST, 3339), anti-HA (CST, 2367), anti-HSP90 (Santa 
Cruz, sc-7947), anti-pAKT (Ser473, CST, 4060), anti-AKT (CST, 9272), anti-p-ERK1/2 (CST, 
4370), anti-ERK (CST, 4695), anti-pMEK (CST, 9154), anti-MEK (CST, 8727), anti-pS6 
(Ser235/236, CST, 4858), anti-S6 ribosomal protein (CST, 2217), anti-p-c-RAF (Ser259, 9421; 
Ser338, 9427), anti-c-RAF (CST, 53745), anti-c-RAF (Santa Cruz, sc-227), and anti-BIM (CST, 
2933). Secondary antibodies included HRP-linked anti-rabbit IgG (CST, 7074) and anti-mouse 
IgG (CST, 7076).  
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Guanine Nucleotide Exchange Assays 
KRAS proteins were preloaded with 2'/3'-O-(N-Methyl-anthraniloyl)-guanosine-5'-[(β,γ)-
imido]triphosphate (Mant-GppNHp; Jena Biosciences) in 20 mM Tris pH 7.5, 50 mM NaCl, 200 
mM (NH4)2SO4 and 0.1 mM EDTA for 2 hrs at 25°C. The Mant-loaded KRAS proteins were 
exchanged into 20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2 and 5 mM EDTA using Zeba 
Spin Desalting Columns (Thermo Fisher Scientific). The Mant-loaded KRAS proteins were 
diluted 8 µM and incubated with p110γ-RBD at 25°C for 1 hr. Nucleotide dissociation was 
initiated by addition of 500-fold excess of unlabeled GTP, and the nucleotide dissociation rate 
was determined by the fluorescence emission at 448 nm (excitation 365 nm) using plate reader 
Synergy NEO (BioTek Instruments). 
 
Human Specimens 
Tumor specimens were obtained from 1,006 NSCLC patients during surgery at the 
Daping Hospital and Research Institute of Surgery, Third Military Medical University, 
Chongqing, China. Western blotting and immunohistochemistry assays were performed as 
previously described (19). The assessment of the staining was scored independently by two 
pathologists without knowledge of the clinicopathological findings. Mutation of KRAS, EGFR, 
PI3K, ALK, and BRAF was detected using SurPlex
TM
 liquid chip at SurExam Bio-Tech Co. Ltd 
(Guangzhou, China). This research was approved by the Research Ethics Board of the Daping 
Hospital and Research Institute of Surgery.  
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Histopathology and Immunohistochemistry 
Tumor tissues from NSCLC patients were fixed in 10% buffered formalin (Sigma), 
embedded in paraffin, and sectioned at 4 µm. The tissue sections were stained with 
Haematoxylin & Eosin (H&E), and performed histopathological analysis. Immunohistochemistry 
was performed as described previously (19), and the IHC staining intensity was scored as 0, 1, 2, 
and 3 (0, none; 1, weak staining; 2, moderate staining; and 3 strong staining). All pathologic 
analysis and IHC scoring were performed by two independent pathologists. To evaluate for the 
percentage of p-AKT or p-ERK staining positive cells, five fields were randomly selected per 
section (at ×40), and counted the total and staining positive cells for each field, then calculated 
the average percentage of cells stained positively. H-score was applied to evaluate for p-AKT 
and p-ERK according to the following formula: H-score = weak intensity (1) × percentage + 
moderate intensity (2) × percentage + strong intensity (3) × percentage. The following antibodies 
were used for immunostaining: p-ERK (CST, 9101) and p-AKT (CST, 4060). 
 
Protein Expression and Purification 
A construct encoding codon-optimized N-terminal His-tobacco etch virus (TEV)-
KRAS
Q61H
 in the pJExpress vector (DNA2.0) was synthesized and used to transform BL21 
(DE3) cells. Cells were grown in Luria broth (LB) to OD600 0.9 and induced with 0.5 M 
isopropyl β-D-1-thiogalactopyranoside (IPTG) for 16 hrs at 16 °C. Cells were pelleted and re-
suspended in lysis buffer [20 mM sodium phosphate (pH 8.0), 500 mM NaCl, 10 mM imidazole, 
1 mM 2-mercaptoethanol (BME), 5% (vol/vol) glycerol] containing 1 mg/mL PMSF and 
benzamidine as protease inhibitor. Lysates were flash-frozen and stored at −80 °C until use. 
Protein was purified over an IMAC cartridge (BioRad) following standard Ni-affinity protocols 
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and desalted into 20 mM HEPES (pH 8.0), 150 mM NaCl, 5 mM MgCl2, and 0.5 mM DTT 
buffer. The N-terminal His tag was cleaved by 24 hrs digestion with a 1:10 ratio of TEV protease 
at 4 °C, and the TEV with His-tag were removed by reverse purification over an IMAC cartridge. 
Protein was concentrated to 30 mg/mL in a 10-kDa cutoff Amicon filter (Millipore), aliquoted, 
and then flash-frozen and stored under liquid nitrogen until use. Yields were ∼8 mg of purified 






were expressed in BL21 (DE3) E. coli. Cells were 
induced by 1 mM IPTG (A600 between 0.6 and 0.8) for 3 hrs at 37
o
C, then homogenized in PBS 
containing 1 mM EDTA, 1% Triton X-100, and 1% protease inhibitor. The lysate was 
centrifuged and resultant supernatant was purified over a GST column. Purified RBDs were 
flash-frozen and stored at −80 °C until use. Yields were ∼10 mg of purified Raf-1-RBD and ∼4 
mg of purified p110γ-RBD per liter of culture.  
 
Crystallization and Structure Solution 
GDP-loaded KRAS Q61H variant were concentrated to 30 mg/ml. Initial crystallization 
trials were performed with a Mosquito (TTPLabTech) crystallization robot using the sitting-drop 
method (100 nl protein plus 100 nl crystallization solution). Right before crystallization set up 20 
mM GTP supplemented in protein. Initial hit at 20 °C with 0.1M MMT and 24% PEG 6000 
observed. The Crystal size and quality were improved using hanging/sitting-drop crystallization 
trials. Diffraction data were collected at SBC beamline 19-ID, Advanced Photon Source at the 
Argonne National Laboratory and processed using HKL3000 (20). Crystal belongs to primitive 
orthorhombic symmetry and diffracted to 2.19 Å. The structure of Q61H was solved by 
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molecular replacement using PHASER in CCP4 suite (21), with the structure of KRAS
WT
 (PDB 
ID: 4OBE) used as search model. There are six KRAS
Q61H
 molecules in the asymmetric unit 
(solvent content 47.5%). After PHASER we could see clear density of GTP at nucleotide binding 
site in each of the six models. Coot (22) was used for model building and PHENIX (23) was 
used for refinement at 2.19 Å resolution. The final atomic model contains six GTP for each of 
the six copies of the GTP-Q61H complex and structure quality monitored by MolProbity (24). 
RMSDs are calculated by lsqkab script in CCP4 suite for structure comparisons and PyMOL 
(The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC) was used for 
structural figures. 
 
Molecular Dynamics (MD) Simulations 
The Schrödinger package on the Maestro platform (Schrödinger release 2016-2, Maestro, 
version 10.6, Schrödinger, LLC) was used to perform molecular dynamics. Systems were 
prepared from high-resolution crystal structures of KRAS
G12D
 mutant bound with GNP (PDB ID: 
5USJ) which was prepared for model construction using the Protein Preparation module, 
including missing atoms addition, H-bond assignment, and restrained minimization. All 
simulation systems were neutralized via adding charge-neutralizing counter ions in a 10 Å 
buffering distance in the SPC solvent model. No ion-excluded region was included. The 50 ns 
simulations were performed using the Desmond Molecular Dynamics module with a constant 
temperature (300 K) and pressure (1.0 bar) in the NPT ensemble. 
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The FRET assay was performed as previously described (12). Briefly, HEK293T cells 
were co-transfected with the paired CFP- and YFP-fused KRAS constructs and c-RAF constructs 
under the condition of 10% FBS in 2-well chambered coverglass (Lab-Tek™). After 36-48 hrs, 
live cell imaging was performed using a Confocal/Multiphoton Zeiss LSM880 microscope. Data 
were collected from three biological repeats and 10–12 different cells in different fields from the 
same coverslip selected for microscopy. Quantitation was done using ZEN software (ZEISS).  
 
Calculation of D154Q dependency ratio 
Western blots were quantitated as described above. Ratios of pERK for WT vs D154Q-
containing specimens were calculated as follows.  
D154Q dependency ratioMAPK
 
D154Q dependency ratioPI3K 
 
Where pERK is the ratio of pERK to tERK. 
 





 Cells (1 × 10
3
) were seeded in 96-well plates in 150 μL DMEM 
complete medium. The following day, plates were treated with selumetinib (Selleck Chem, 100 
nM), trametinib (Selleck Chem, 10 nM), or RAF709 (Selleck Chem, 1 µM) alone or in 
combination and incubated in the IncuCyte Zoom for real-time imaging, with three fields imaged 
per well under 10x magnification every 2 hrs. Data were analyzed using the IncuCyte 
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Confluence version 1.5 software, which quantified cell surface area coverage as confluence 
values. IncuCyte experiments were performed in triplicate. A single representative growth curve 
is shown for each condition.  
To assess the effects of D154Q on cell growth, DOX inducible Flp-In T-REx 293 cells (1 
× 10
3
) expressing KRAS G12D, G13D, and Q61H and the counterparts with D154Q mutation 
were seeded in black 96-well plates with clear bottom in 200 μL DMEM complete medium with 
supplement of DOX (2 ng) and incubated in the IncuCyte Zoom for real-time imaging, with three 
fields imaged per well under 10x magnification every 4 hrs. Data were analyzed using the 
IncuCyte software, which counted red cell nucleus (mCherry-H2B location) as cell number. 
IncuCyte experiments were performed in triplicate.  
 
Drug Sensitivity Assay 





Rasless MEF cells when treated alone or in combination. Cells (1 × 10
3
) were seeded in 96-well 
plates in DMEM complete medium. The following day, cells were treated with selumetinib, 
trametinib, or RAF709 alone using a ten-point dose titration scheme from 1 nM to 10 M, from 
1 nM to 1 M, from 1 nM to 10 M, respectively. In addition, cells received a combinatorial 
treatment with selumetinib or trametinib at various concentrations and a fixed concentration of 
RAF709 at 1 µM; or with RAF709 at various concentrations and a fixed concentration of 
selumetinib and trametinib at 1 µM and 10 nM, respectively. After 72 hrs, cell viability was 
assessed using colorimetric MTS assay (CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay (MTS) Powder, Promega). Absolute inhibitory concentration (IC) values 
were calculated using four-parameter logistic curve fitting. All experimental points were a result 
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of three to six replicates, and all experiments were repeated at least three times. The data was 
graphically displayed using GraphPad Prism 5 for Windows (GraphPad Software). Each point 
(mean ± standard deviation) represents growth of treated cells compared to untreated cells. The 
curves were fitted using a non-linear regression model with a sigmoidal dose response. 
 
Drug Synergy Analysis 
Cells were plated at a concentration of 1,000 cells/well in a 384 well plate and allowed to 
settle for 24 hrs. The cells were then treated with a serial dilution of drugs in a 7×7 format with 
up to 6 repeats per plate using an HP D300e Digital Dispenser. After an additional 72 hrs, 
CellTiter-Glo reagent was added to each well and the luminescence readout was evaluated by a 
POLARStar Omega Plate Reader. The relative viability was then calculated by dividing the 
reading of each well by the reading from the untreated control. The program Combenefit (25) 
was then used to calculate a Bliss Synergy Score for each drug combination and generate graphs, 
with higher scores indicating greater synergy. The number of asterisks below the synergy score 










 cells (1 × 10
6
) were injected subcutaneously in a 1:1 mix of serum-free 
DMEM and Matrigel (phenol red–free; BD Biosciences) in both flanks of recipient mice. Once a 
palpable tumor formed, measurements were taken daily using calipers. Drug-naïve mice bearing 
established tumors of 240 to 300 mm
3
 were randomly assigned to either selumetinib or vehicle 
treatment. Selumetinib, solubilized in 1% carboxymethyl cellulose (CMC), 0.25% Tween 80 was 
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administered daily by oral gavage (0.1 mL/10 g body weight) at a dose of 50 mg/kg in drug-
naïve mice. Animals randomly assigned to experimental treatment groups were dosed by oral 
gavage without blinding at any stage of the study. Welfare-related assessments and interventions 
were carried our daily during the treatment period. All care and treatment of experimental 
animals were in strict accordance with Good Animal Practice as defined by the US Office of 
Laboratory Animal Welfare and approved by the Dana-Farber Cancer Institute Institutional 
Animal Care and Use Committee. 
 
 
Statistical and Data Analysis 
Unless otherwise specified, data are presented as mean ± SD. Significance between two 
groups was assessed by the Student's two-tailed t-test. Data sets consisting of more than 2 groups 
were analyzed by analysis of variance (ANOVA). A p value that was less than 0.05 was 
considered statistically significant for all data sets. All statistical analysis was performed using 
GraphPad Prism software. No statistical method was used to predetermine sample size in animal 






 Preferentially Binds to c-RAF  
We previously evaluated the relative binding affinities of a panel of activating RAS mutants 
for RAF in a purified system and found a range of values (16). We speculated that this could lead 
to preferential signaling events, but considered that comparisons to interactions with other 
canonical RAS effectors may provide additional insights. We applied three different approaches 
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to determine if KRAS
Q61H
 preferentially interacts with c-RAF as compared to the catalytic 
subunit of type I PI3K, also known as p110α and p110γ, which regulates cell cycle, survival, 
metabolism, and other processes (26) (Fig. 1A). As a control, we included KRAS
G12D
, which has 
been demonstrated to signal through both PI3K and MAPK pathways (27), and KRAS
G13D
 which 
shows intermediate binding affinity toward RAF (16). We first used c-RAF-RBD or p110γ-RBD 
to pull down mutant KRAS expressed in HEK293T cells in the presence of 10% FBS to 
stimulate RAS signaling. KRAS
Q61H





 showed a minor, though statistically significant, enhancement in 
binding to p110γ-RBD compared to KRAS
Q61H
 (Fig. 1B and 1C), suggesting KRAS
Q61H
 
preferentially binds to c-RAF-RBD.  
To evaluate if these preferential protein-protein interactions also occur in cells, we used 
CETSA that evaluates protein stability in situ (18). In this technique, proteins that are resistant to 







 for the ability to interact with c-RAF or 
p110α. c-RAF was more stable in the presence of KRAS
Q61H







 also enhanced c-RAF thermal stability to some degree over 
KRAS
WT
 (Fig. 1D). On the other hand, p110α was more resistant to thermal exposure in the 
presence of KRAS
G12D
 and, to a lesser degree, KRAS
Q61H
, in comparison to KRAS
WT 
(Fig. 1E). 
We also tested KRAS thermal stability, but saw no statistical difference between KRAS mutant 
samples irrespective of c-RAF or p110α expression (Supplementary Fig. S1A and S1B).  





in the presence of p110γ-RBD. Productive binding between RAS and p110γ-RBD would be 
predicted to slow the dissociation of nucleotide from RAS. We observed this for KRAS
G12D
 but 
on July 13, 2020. © 2020 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 




saw no stabilizing effect for KRAS
Q61H
, suggesting a lack of interaction between KRAS
Q61H
 and 
p110γ-RBD within the bounds of this assay (Supplementary Fig. S1C and S1D). Taken together, 
these results suggest that KRAS
Q61H







 NSCLC Preferentially Signals through MAPK  




 and c-RAF or 
p110γ predict that corresponding effects will propagate to intracellular signaling. We 
hypothesized that KRAS
Q61H
 mutations in patients would also show a preferential signaling 
pattern through MAPK over PI3K/AKT. To explore this, we examined MAPK and PI3K/AKT 
signaling activity in NSCLC patient specimens. We screened 1,006 NSCLC patient frozen 
specimens for mutations in KRAS, EGFR, PI3K, ALK, or BRAF and identified 59 cases with 
KRAS mutations (Fig. 2A), which is consistent with reported mutation frequency in Asian with 
high EGFR (30%-40%) and low RAS (3%-8%) mutation (28,29). Of these, three contained 
KRAS
Q61H
 mutations. A summary of the study population is given in Table S1. We randomly 




 mutations for comparison. By IHC 
analysis, both oncogenic KRAS mutations showed higher levels of p-AKT and p-ERK as 
compared to wild-type KRAS. However, KRAS
G12D
-driven NSCLC showed more prominent p-
AKT staining compared to KRAS
Q61H
-containing NSCLC (Fig. 2B and C). To further quantify 
these differences, Western blots of tumor tissues showed a significantly higher level of p-ERK 
signaling in KRAS
Q61H
 samples as compared to KRAS
G12D
 samples, while p-AKT levels were 
significantly higher in KRAS
G12D
 compared to KRAS
Q61H
 specimens (Fig. 2D and E; 
Supplementary Fig. S2A and S2B). The RAS level was not significantly different in KRAS
G12D
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 specimens (Fig. 2D and E, Supplementary Fig. S2A and S2B). These data suggest 
that the preferential signal output of KRAS
Q61H
 through MAPK signaling pathway also occurs in 
NSCLC clinical specimens.  
 
A Hyper-dynamic Switch 2 Explains Preferential MAPK Signaling 
The selective preferential interactions of KRAS
Q61H
 for MAPK argues that the Q61H 
mutation causes structural changes in KRAS
Q61H
 that are not seen in KRAS
G12D
. We solved an 
X-ray crystal structure of KRAS
Q61H
 lacking a hypervariable C-terminal domain (residues 1-169) 
in complex with GTP (Supplementary Table S2; Fig. 3A-F). The fact that we were able to use 
GTP instead of a non-hydrolysable analogue is a remarkable re-demonstration of the negligible 
GTPase activity of this mutant (16) because protein crystallization takes 2-3 days. Crystals were 
in the P212121 space group such that six molecules were in the asymmetric unit. Unambiguous 
electron density was observed for all molecules except for two residues in molecule A and three 
residues in molecule F (missing residues: Chain A 64 and 65; Chain F 62-64). Density was also 
observed for GTP, a magnesium ion, and water molecules (Fig. 3B). The conformation 
resembles previously reported GTP analogue-bound RAS structures with the exception of the 
rearrangement of switch 2, which, when all 6 molecules from the asymmetric unit are 
superimposed and compared, presents an ensemble of backbone and residue 61 sidechain 
conformations (RMSD 4.6 Å) within the crystal lattice (Fig. 3G). This is dissimilar to prior GTP-
analogue bound RAS structures including KRAS
Q61H
-GMPPNP (PDB ID: 3GFT), HRAS
G12D
-
GMPPNP (PDB ID: 1AGP), KRAS
G12D
-GMPPNP (PDB ID: 5USJ), and HRAS
G12C
-GMPPNP 
(PDB ID: 4L9W) where the position of codon 61 sidechains generally align (RMSD 0.8 Å), 
approximately 6 Å from the γ phosphate (Fig. 3H). The average B-factors of switch 2 residues 
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are around 2-fold higher than the rest of the structures, reflecting their dynamic character. On the 
other hand, switch 1 is well-ordered and resembles the previously described ‘state 2’ of GTP-
bound RAS (30).  
Given the array of side chain positions in residue 61, we inferred that altered interactions 
upon mutation of Gln to His drive the conformational dynamics of switch 2. To further 
demonstrate this effect, we performed MD simulations extending over 50 ns using a high-
resolution X-ray structure of KRAS
G12D
-GNP (PDB ID: 5USJ) as the seed model. In simulations 
pertaining to KRAS
Q61H
, the side chain of residue 61 was computationally mutated to His 
without additional alterations. We examined the distances between the side chain nitrogen of 
residue 61 (Q or H) and γ phosphate of GTP over the course of the simulation (Fig. 3I). 
Compared to Q61, H61 rapidly moves away from the gamma phosphate early in the simulation 
and tends to remain separated (Fig. 3J). To rationalize this effect, we considered that in other 
GTP-bound RAS structures, with the exception of other Q61 mutants, Q61 typically engages in a 
hydrogen bond network involving multiple side chains, water molecules, and the phosphate 
oxygens (Supplementary Fig. S3A and S3B). This includes contributions from Gln61, Glu62, 
Tyr64, Ala68, and Tyr96 which, in concert, hold switch 2 in a ‘closed’ conformation, bringing 
most of these side chains into close proximity with the gamma phosphate as seen in the structure 
of KRAS
G12D
-GMPPNP (PDB ID: 5USJ) (Supplementary Fig. S3B). Of note, bridging waters, 
which normally play a role in catalysis, are key components of these interactions (31). With the 
mutation of Gln to His at position 61, the side chain no longer interacts with a key bridging 
water, leading to a breakdown in the remaining network and an unconstrained switch 2 (Fig. 3G-
I). An unconstrained, hyper-dynamic switch 2 that does not interact significantly with the 
adjacent switch 1, is expected enable a more stable conformation of switch 1. This is because 
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switch 2 has the ability to induce more dynamic behavior in switch 1 under normal 
circumstances (32,33). A more stable conformation of switch 1 has the potential to lead to 
improved interactions with RAF, since switch 1 serves as the primary interface for RAS-RAF 
interactions (34). 
Modeling our structure into prior structures of RAS in complex with effector proteins 
provides an additional possible reason why a dynamic switch 2 could lead to differential RAS-
effector interactions. We superimposed our model of KRAS
Q61H
-GTP onto that of HRAS
G12V
-
GNPPNP-p110γ (PDB ID: 1HE8) and HRAS-GNPPNP-RAF-RBD (4G0N). We noted that 
increased switch 2 flexibility has the potential to clash with p110γ, especially Tyr64 of 
KRAS
Q61H
 and Phe221 of p110γ which are in close contact (Supplementary Fig. S4A and S4B). 
However, with RAF-RBD, we note that increased switch 2 flexibility has the potential to 
enhance interactions between switch 1 and the RBD (Supplementary Fig. S4C) (33). 
Collectively, these observations suggest two possible structural mechanisms by which KRAS
Q61H
 
could favor binding to RAF-RBD over p110α/γ-RBD.  
   
KRAS
Q61H 
oligomerization and c-RAF dimerization are Interdependent 
Interactions between RAS and p110α/γ or c-RAF might also be influenced by RAS-RAS 
interactions, which was previously shown to be important for RAS
WT
-dependent suppression of 
cell growth (12). Interdependence of RAS-RAS and RAF-RAF interactions also seemed possible 
given that both are known to form complexes, and interactions between c-RAF and RAS are 
required to overcome the autoinhibitory function of the c-RAF N-terminal regulatory (NTR) 
region, allowing c-RAF to dimerize at the cell membrane (35). Additionally, ‘cooperativity’ 
between RAS and RAF is a component of proposed mechanisms of paradoxical MAPK signaling 
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in the presence of RAF inhibitors (36,37). Of note, we did not expect to see such cooperativity 
with PI3K, because PI3K multimerization is not known to occur. Moreover, extrapolation based 
on the structure of HRAS-p110γ (38), to include p110γ in our RAS dimer model predicts against 
any interaction between individual p110 protomers bound to dimerized RAS (Supplementary 
Fig. S5). Given the increased affinity of KRAS
Q61H
 for RAF, and the lack of GTPase activity in 
KRAS
Q61H
 which would be expected to allow for stable complex formation, we hypothesized 
that KRAS
Q61H
, in particular, may show dependence on the formation of RAF dimers. Prior work 
showed that the D154Q substitution in KRAS was sufficient to disrupt KRAS-KRAS 
interactions at the cell membrane that occur via the KRAS α4-α5 interface, but did not alter the 
baseline biochemical properties of KRAS such as GTPase activity or affinity for RAF (39). The 
D154Q mutation also abolished the suppressive effects of KRAS
WT
 seen in the genetic 
background of oncogenic KRAS. This was shown in the Rasless MEF model in vitro and in vivo, 
and in multiple cancer cell lines. Our interpretation was that the suppressive effects of KRAS
WT
 
occur through direct RAS-RAS interactions (12). Here we used the same mutation to study the 
impact of D154Q in the context of RAS
Q61H
. Surprisingly, addition of D154Q impaired capture 
of KRAS
Q61H






 recovery. On the 
other hand, D154Q did not impact recovery by p110γ (Fig. 4A-C). Together these results suggest 
that KRAS multimerization influences interactions with c-RAF for KRAS
Q61H
 but not p110γ in 
this cellular context. 
To further evaluate interdependence between RAS and RAF interactions, we used a cell-
based FRET assay to examine the influence of c-RAF interactions on KRAS and c-RAF 
multimerization (12). In the RAS assay, a CFP donor and an YFP acceptor are fused to the N-
terminus of KRAS (Supplementary Fig. S6A-F). If CFP and YFP are adjacent, CFP is excited 
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and energy is transferred to YFP. However, CFP emission increases upon photobleaching due to 
loss of energy absorption by YFP. If CFP and YFP are spatially separated, no change in CFP 
emission is observed due to the absence of energy transfer from CFP to YFP (please see Fig S3B 




 showed FRET in the 
presence of c-RAF
WT
 that was minimally attenuated by the introduction of R89L into c-RAF, a 
mutation known to disrupt the RAF-RAS interaction for WT or KRAS
G12D 
(40) (Fig. 4D; 
Supplementary Fig. S6A and S7A). However, KRAS
Q61H
 multimerization was not detectable 
with introduction of R89L suggesting that KRAS
Q61H
 depends on c-RAF for multimerization 
(Fig. 4D).  
We noted that a RAS-RAS interaction can be also be detected without the introduction of 
exogenous c-RAF in the presence of 10% FBS (Supplementary Fig. S6B and S6C), suggesting 
that endogenous c-RAF is sufficient to influence RAS multimerization. We posited that 
exogenous c-RAF
R89L
 acts indirectly upon RAS multimerization by sequestering endogenous 
RAF by RAF multimerization, leading to loss of FRET signal (Fig. 4E). To confirm this we 
introduced a second mutation R401H, which is known to disrupt RAF-RAF multimerization, to 





 multimerization (Fig. 4F; Supplementary Fig. S6D and S7A). 
Of note, MAPK signaling in the cell samples used for FRET was concordant with FRET results 
(Supplementary Fig. S7B). Specifically, overexpression of exogenous c-RAF
R89L
 reduced c-RAF 
and ERK phosphorylation and for all forms of KRAS. However, the effect was more prominent 
in the context of KRAS
Q61H
 (Supplementary Fig. S7B) suggesting that KRAS
Q61H
 is regulated by 
RAF multimerization. Also similar to the FRET result, introduction of the combination of 
R401H and R89L mutations into c-RAF recovered p-ERK for KRAS
Q61H
 but not KRAS
G12D
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(Supplementary Fig. S7B), suggesting that release of sequestered endogenous RAF leads to 
restoration of an interdependent c-RAF- KRAS
Q61H
 complex, but the same interdependence with 
c-RAF does not apply to KRAS
G12D
. In aggregate, these results support that c-RAF 
multimerization is critical for regulation at the level of KRAS
Q61H




The availability of this system also allowed us to examine if KRAS multimerization may 
similarly impact c-RAF multimerization. This question arises from work showing that certain 
RAF mutations are RAS-dependent for RAF multimerization (42). We measured the dependence 
of RAF multimerization on RAS multimerization using a c-RAF FRET assay similar in principle 
to the RAS multimerization assay. This assay is also similar in concept to previously reported 
BRET assays used to measure RAF interactions (43). In this assay c-RAF multimerization 
required overexpression of exogenous KRAS, but was lost upon introduction of D154Q 
demonstrating that c-RAF multimerization was dependent on RAS multimerization (Fig. 4G; 
Supplementary Fig. S6E and S6F). Taken together, these results demonstrate that KRAS
Q61H
 and 




-mediated MAPK Signaling Is RAS multimer-dependent  
To understand if the interdependence of RAF and KRAS dimers translates into biological 




-dependent signaling in 
HEK293T cells expressing exogenous mutant KRAS proteins, focusing on p-ERK and p-AKT as 
indicators. Consistent with binding studies and patient tissue analysis (Fig. 1B and C; Fig. 2D 
and E), KRAS
Q61H
 demonstrated enhanced activation of ERK relative to AKT, while KRAS
G12D
 
showed activation of both ERK and AKT (Fig. 4H). Addition of the D154Q mutation 
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significantly reduced p-ERK levels, while p-AKT levels were less affected. To better appreciate 
the impact of RAS mutations on multimerization for the MAPK vs. PI3K pathways, we 
quantitated a “D154Q dependency ratio” that consists of the ratio of p-ERK or p-AKT in the 
presence of WT vs. D154Q mutated KRAS as defined in the methods section. KRAS
Q61H
-





 (Fig. 4I). Additionally, for G13D and Q61H, MAPK signaling was sensitive to 
D154Q, whereas PI3K signaling was not. These results were reflected in the growth of these 
cells such that introduction of the D154Q into the exogenously-expressed KRAS also impaired 
cell growth (Fig. S8). Collectively, these results support that preferential interactions between 
KRAS
Q61H
 and c-RAF rely on RAS multimerization to produce disproportionate up regulation of 




 Is a Marker of Sensitivity to MEK Inhibitors and an Allosteric RAF Inhibitor in 
vitro and in vivo 
The observations that KRAS
Q61H
 preferentially signals through MAPK and depends on 
RAF multimerization raises the possibility that KRAS
Q61H
 bearing cells will be sensitive to 
inhibitors of these mechanisms. In particular we anticipated that RAF inhibitors that function in 
the context of the RAF dimer, such as RAF709 (44), would show increased activity in KRAS
Q61H
. 
We exposed isogenic RAS-dependent MEF cells (12) to MEK inhibitors selumetinib and 
trametinib and RAF709. This system is derived from Ras-less mouse embryonic fibroblasts 
(MEFs) (17), in which the endogenous HRas and NRas alleles are constitutively knocked out and 
conditional KRas alleles are under the control of a resident 4OHT-inducible CRE recombinase, 
so that cells are dependent on introduction of an exogenous Ras gene for growth. For these 
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 MEFs were more sensitive to selumetinib and trametinib 




 MEFs for cell growth and proliferation. IC50 values for both 
selumetinib and trametinib were roughly 5-fold lower for Q61H as compared to G12D (Fig. 5A 
and B). However, we noted ~15-fold difference upon exposure to RAF709 (Fig. 5C) in favor of 
Q61H. A similar effect was also seen for both overall proliferation and growth kinetics (Fig. 5D). 









MEFs, whereas either selumetinib or trametinib co-
treatment further increased IC50 to RAF709 (Supplementary Fig. S9). Correspondingly, 









 MEFs as single agents 
(Supplementary Fig. S10A). We also evaluated for induction of the Bcl-2 family member BIM 














 cells when exposed to selumetinib, 
trametinib, or RAF709 alone (Supplementary Fig. S10A).  









 cells treated with selumetinib. Remarkably, tumors shrank 
in the Q61H group in response to selumetinib, while the G12D showed continued slow growth 
without evidence of actual tumor regression (Fig. 5G and Supplementary Fig. S10D).  









enhanced sensitivity to combination treatment with MEK inhibitor and RAF709 (Fig. 5D; 
Supplementary Fig. S9; Supplementary Fig. S10B and S10C). We therefore evaluated for 
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synergy between RAF and MEK inhibition and found synergistic effects in both systems, as 
measured using the Bliss independence dose–response surface model (25,46). Bliss scores more 
than zero indicate combinations where the effect is greater than additive. Of note, synergistic 





 (Fig. 5E and F; Supplementary Fig. S11A and S11B). Moreover, the 





(Supplementary Fig. S10A).  
 
Discussion 
Here we established that KRAS
Q61H
 has a negligible intrinsic GTPase activity and a 
preferential interaction with RAF proteins over PI3K. In essence, the combination of the 
negligible GTPase activity and enhanced interaction with RAF appears to partially sequester 
KRAS
Q61H
 into signaling though the MAPK pathway. The structural mechanism arises from 
disengagement of the switch 2 of RAS from the gamma phosphate of GTP, which both ablates 
GTPase activity and enhances interactions with RAF, but decreases interactions with p110γ. The 
enhancement of RAS-RAF interactions in turns leads to an interdependence of RAS and RAF 
multimerization. One result of this interdependence appears to be that KRAS mutant tumors 
bearing KRAS
Q61H
 are more sensitive to inhibition of MAPK signaling at the level of RAF and 
MEK. 
These observations may explain the rarity of KRAS
Q61H
 mutations overall, either because it 
lacks sufficient interactions with PI3K which are essential for supporting RAS-driven 
tumorigenesis in certain contexts (47), or because unrestrained MAPK signaling leads to 
deleterious effects (48) in the absence of other, as yet unknown, compensatory factors. These 
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results also provide motivation for clinical trials exploring MAPK pathway inhibitors in 
mutational subsets of RAS-driven cancers. Specifically, these findings suggest that cancerous 
tumors bearing KRAS codon 61 mutations will be more sensitive to the inhibition of MAPK 
signaling pathway via MEK or ‘paradox-breaking’ RAF inhibitors as compared to codon 12 and 
13 KRAS mutations.  
Our findings also expand the understanding of the context-dependence of RAS 
multimerization/clusterization with respect to RAS mutations and effector interactions. 
Specifically we establish that an interdependence between RAS and RAF multimerization plays 
a special role with KRAS
Q61H
, not seen with KRAS
G12D
. Additionally, the D154Q substitution 
did not affect PI3K activity for either mutant, suggesting that RAS multimerization plays a role 
in MAPK, but not PI3K signaling. This property raised the hypothesis that KRAS
Q61H
 would 
show enhanced sensitivity to the RAF inhibitor RAF709, which was confirmed in our model 
systems (44). However, whether this finding is generalizable to human lung cancers, which are 
notoriously heterogeneous, will require additional study. Another important question is whether 
similar effects will be seen with NRAS or HRAS-related cancers, where codon 61 mutations are 
more common. 
It bears mentioning that the structure of the RAS multimer remains a topic of open debate. 
Multiple structural models have been proposed, with variable levels of experimental data (13-
15,49). This likely reflects the low affinity of RAS-RAS interactions and that they rely on cell 
membrane association to occur. These characteristics lead to experimental challenges which have 
prevented rapid progress in solving structures. First, RAS-RAS interactions appear to be low 
affinity and dependent on association with the cell membrane making RAS complexes difficult 
to isolate. Second, RAS complexes may take multiple forms, making structural studies difficult 
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because most methods rely on obtaining a mono-dispersed population of structural conformers. 
As of now, the D154Q and R161E mutations are the only mutations we are aware of that appear 
to disrupt RAS multimers without altering other core biochemical functions of RAS. However, 
as new structural data becomes available, it may be possible to better delineate the conditions 
that dictate which structural forms occur and when and how to manipulate them.  
If these findings can be validated in a larger set of human cancer specimens, they would 
have clinical significance, given the apparent difference in sensitivity of KRAS
Q61H
-driven 
tumors to pharmacological MAPK inhibition. This idea is consistent with a trend towards clinical 
benefit in patients with codon 61 mutations in the SELECT-1 trial which tested the MEK 
inhibitor selumetinib in the context of KRAS-mutated lung cancer (50). It is worth noting that 
another KRAS mutation, KRAS
G12R
 found in pancreatic cancer, also demonstrated a preference 
for MAPK signaling, prompting the initiation of a clinical trial of the MEK inhibitor selumetinib 
(NCT03040986). Together these studies highlight the possibility that trials of MAPK pathway 
inhibitors may turn positive if patient selection criteria is further refined to only include sensitive 
RAS mutations.  
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 interacts preferentially with RAF-RBD over p110α/γ-RBD. (A) A 
schematic model for preferential interactions between KRAS G12D or Q61H and downstream 
effectors RAF or p110. (B) Immunoprecipitation of CFP-tagged RAS mutants using c-RAF or 
p110γ RBDs. HEK293T cells were harvested after 48 hrs transfection with CFP-tagged KRAS 
mutants in the presence of 10% FBS. The protein samples were subject to pull-down and 
Western blotting assay. IP, immunoprecipitation; WT, wild type; exp, exposure. (C) Quantitation 
of Fig. 1B demonstrates enhanced interactions between c-RAF-RBD and KRAS
Q61H
 relative to 
KRAS
G12D
 but not with p110γ-RBD (n = 3). (D, E) KRAS
Q61H
 enhances the thermal stability of 
c-RAF expressed in HEK293T cells relative to other RAS mutations. However, KRAS
G12D
 
enhances the thermal stability of PI3K subunit p110α relative to other RAS mutations. Bars 
represent quantitation of blots above. HEK293T cells were harvested after 48 hrs co-transfection 
of KRAS mutants with c-RAF or p110α in the presence of 10% FBS. The protein samples were 
subject to thermal exposure and the resultant supernatants were subject to Western blotting assay 
for testing the remaining level of c-RAF, p110α, or RAS (n = 3). WT, wild type. For all bar 
graphs, data are presented as mean ± SD. * p<0.05, ** p<0.01, and *** p<0.001 compared to 
KRAS
G12D
 (Two-way ANOVA). 
 





. (A) Screening results of NSCLC patient specimens for KRAS 
mutations. In total, there were 1,006 NSCLC patient tumor samples selected for KRAS, EGFR, 
PI3K, ALK, and BRAF sequencing and three samples were KRAS
Q61H
 mutant. (B) 
Immunohistochemical staining for p-AKT and p-ERK in patient specimens demonstrate 
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increased p-ERK in KRAS
Q61H
 patients relative to KRAS
G12D
 and increased p-AKT in 
KRAS
G12D
 patients relative to KRAS
Q61H
 (scale bar: 100 µm). WT, wild type. (C) H-scores of p-
AKT and p-ERK levels from IHC staining samples (n = 15). WT, wild type. (D, E) 
Representative blots and associated quantitation from frozen tissue specimens for p-AKT and p-
ERK in NSCLC patient specimens (n = 3). WT, wild type; ns, no significance. For all graphs, 
data are presented as the mean ± SD.  
 
Fig. 3. Crystal structure of KRAS
Q61H





 demonstrating alterations in switch 2 (green) conformation. Switch 1 
is in yellow and GTP in sticks. Difference Fourier Fo-Fc electron density map of GTP at 3σ 
contour level is shown in green in B. (G) Superimposition of the 6 molecules in the asymmetric 
crystallographic unit reveals an ensemble of backbone and His61 conformations in KRAS
Q61H
. 
(H) Structure comparison of HRAS
G12C
:GMPPNP (4L9W) in light magenta, 
KRAS
Q61H
:GMPPNP (3GFT) in dark salmon, HRAS
G12D
:GMPPNP (1AGP) in pale yellow, 
KRAS
G12D
:GMPPNP (5USJ) in slate, Mg
2+
 in sphere (magenta), GTP and Gln61 are in sticks. (I) 
Distances between side chain nitrogen of residue 61 and γ phosphate of GTP are shown in red 




. (J) Distance between the side chain 




Fig. 4. RAF and KRAS
Q61H
 multimerization are cooperative. (A) Immunoprecipitation of 
active form of CFP-tagged KRAS WT, G12D, G13D, and Q61H and the counterparts with 
D154Q mutants, using c-RAF or p110γ RBDs. D154Q is added to prevent RAS multimerization. 
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HEK293T cells were harvested after 48 hrs transfection with CFP-tagged KRAS mutants in the 
presence of 10% FBS. The protein samples were subject to pull-down and Western blotting 
assay. IP, immunoprecipitation; WT, wild type. (B, C) Quantitation of Fig. 4A demonstrates that 
KRAS
Q61H
 multimerization influences interactions with c-RAF but not p110γ. Data were 
normalized to KRAS
G12D
 and the RAS-GTP level for KRAS mutants was compared in the 
presence or absence of D154Q mutation (n = 3). IP, immunoprecipitation; WT, wild type. (D) 
CFP emission after photobleaching indicates multimerization between CFP and YFP-fused 
KRAS. All KRAS mutants except for Q61H retain the ability to dimerize regardless of 
expression of exogenous c-RAF, including the dimer-incompetent form R89L. HEK293T cells 
were co-transfected with c-RAF, CFP-KRAS, and YFP-KRAS constructs and subject to confocal 
microscopy for FRET assay. WT, wild type. (E) Schematic of RAS-RAF cooperativity. Left, a 
cooperative RAS-RAF heterotetramer including autoregulatory CRD and RBD domains of 
endogenous c-RAF (blue). Middle, introduction of exogenous c-RAF
R89L
 (green) impairs 
KRAS
Q61H
 multimerization by heterodimerizing with endogenous c-RAF. However, introduction 
of exogenous c-RAF
R89L/R401H
 which is unable to dimerize with endogenous c-RAF, allows 
recovery of KRAS dimers (right). WT, wild type; CRD, cysteine-rich domain; RBD, Ras-
binding domain; KD, kinase domain. (F) CFP emission after photobleaching indicates 




. Introduction of 
R401H into c-RAF
R89L
 restored FRET signal for KRAS
Q61H
. The FRET assays were performed 
in HEK293T cells co-transfected with c-RAF, CFP-KRAS, and YFP-KRAS constructs via 
confocal microscopy. (G) FRET from multimerization of fluorescent-tagged c-RAF is not 
observed by the dimer-disrupting mutation D154Q in KRAS. HEK293T cells were co-
transfected with c-RAF-CFP, c-RAF-YFP, and KRAS constructs and subject to confocal 
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microscopy for FRET assay. All FRET data are presented as the mean ± SEM. WT, wild type. 
(H) Signal transduction in HEK293T cells demonstrates a preference for MAPK signaling for 
KRAS
Q61H




. HEK293T cells were harvested after 48 hrs co-
transfection of KRAS mutants in the presence of 10% FBS. The protein samples were subject to 
Western blotting assay for testing RAS signals. WT, wild type. (I) Quantitative comparison of 
the “dimer dependency” ratio consisting of the ratio between normalized MAPK signal (p-
ERK/t-ERK) or PI3K (p-AKT/t-AKT) for dimer-competent vs. dimer-impaired (D154Q) KRAS. 





. WT, wild type. For all graphs related to blots, data are presented as 
the mean ± SD. *p<0.05 and ***p<0.001 (Two-way ANOVA). 
 
Fig. 5. Differential responses upon the exposure to MEK and RAF inhibitors in vitro and in 









 demonstrate higher 
sensitivity for Q61H relative to G12D. Data are presented as mean ± SD of cell lines belonging 
to each group. IC50 values were 1,140 nM vs. 224 nM for selumetinib, 10 nM vs 2 nM for 
trametinib, 4,300 nM vs. 300 nM for RAF709 for G12D and Q61H, respectively. (D) Cell 









 in the absence of endogenous wild-type KRas alleles upon exposure to Sel (100 nM), 
Tra (10 nM), or RAF709 (1 µM) alone or in combination. Results were assessed by IncuCyte 
measurements and are representative of one of three similar experiments. Sel, selumetinib; Tra, 
trametinib. (E, F) Differential synergistic effects of RAF inhibitor in combination with MEK 




 MEFs expressing exogenous HA-tagged 
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 upon the exposure to RAF709 in combination with trametinib. Positive 
score indicates combinations where the effect is greater than additive. (G) Fold volume change 









 when treated with Sel (50 mg/kg daily). Sel, selumatinib.  
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